Almost half (48.4%) of our lung cancer patients had lung squamous cell carcinoma (SCC), which is often perceived to lack molecular targets, however our results suggest that KRAS, PIK3CA, PTPN11 and CDKN2A, in particular, could potentially be actionable targets in lung SCC. The gene discussed is KRAS; the disease is lung carcinoma.